Xcell Therapeutics Inc. Stock: price and insider trades · South Korea

Xcell Therapeutics Inc. is a Health Care company. Its directors and officers file their transactions with DART (FSS). The last twelve months, up to 1 November 2026, brought 16 filings signed by 8 insiders.

Open-market activity splits into 10 purchases totalling €28k and 3 sales totalling €132k; 6 insiders sit on the buying side and 2 insiders on the selling side. The totals do not cover 6 filings with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. 이의일 filed the largest sale, €132k, on 1 April 2026, which represents 1.1% of the company's market value. Among those who bought: 5 senior executives and 1 major shareholder.

Across the 2,655 companies tracked on its exchange, the median is 7 filings; at 16 filings, this issuer sits above that mark. Since 2024, the database holds 12 purchases and 5 sales by insiders of the company.

In all, 5 purchases were made within 30 days of a purchase by another insider of the company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last purchase on record was published on 1 April 2026, which is 223 days ago. Typically, a trade is published a median of 4 days after it takes place. That lag is the time during which only the insider knows about the trade.

Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and UCB. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.